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Background: Secretory signal peptides (SPs) are well-known sequence motifs targeting proteins for translocation
across the endoplasmic reticulum membrane. After passing through the secretory pathway, most proteins are
secreted to the environment. Here, we describe the modification of an expression vector containing the SP from
secreted acid phosphatase 1 (SAP1) of Leishmania mexicana for optimized protein expression-secretion in the
eukaryotic parasite Leishmania tarentolae with regard to recombinant antibody fragments. For experimental design
the online tool SignalP was used, which predicts the presence and location of SPs and their cleavage sites in
polypeptides. To evaluate the signal peptide cleavage site as well as changes of expression, SPs were N-terminally
linked to single-chain Fragment variables (scFv’s). The ability of L. tarentolae to express complex eukaryotic proteins
with highly diverse post-translational modifications and its easy bacteria-like handling, makes the parasite a
promising expression system for secretory proteins.
Results: We generated four vectors with different SP-sequence modifications based on in-silico analyses with
SignalP in respect to cleavage probability and location, named pLTEX-2 to pLTEX-5. To evaluate their functionality,
we cloned four individual scFv-fragments into the vectors and transfected all 16 constructs into L. tarentolae.
Independently from the expressed scFv, pLTEX-5 derived constructs showed the highest expression rate, followed
by pLTEX-4 and pLTEX-2, whereas only low amounts of protein could be obtained from pLTEX-3 clones,
indicating dysfunction of the SP. Next, we analysed the SP cleavage sites by Edman degradation. For pLTEX-2, -4,
and -5 derived scFv’s, the results corresponded to in-silico predictions, whereas pLTEX-3 derived scFv’s contained
one additional amino-acid (AA).
Conclusions: The obtained results demonstrate the importance of SP-sequence optimization for efficient
expression-secretion of scFv’s. We could successfully demonstrate that minor modifications in the AA-sequence in
the c-region of the natural SP from SAP1, based on in-silico predictions following the (-3, -1) rule, resulted in
different expression-secretion rates of the protein of interest. The yield of scFv production could be improved close
to one order of magnitude. Therefore, SP-sequence optimization is a viable option to increase the overall yield of
recombinant protein production.
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Leishmania tarentolae is a eukaryotic flagellated unicel-
lular parasite with a broad range of applications [1-3].
An increasing field of interest is its use as a host for re-
combinant protein expression [4-8]. It allows complex
eukaryotic protein expression at high levels compared
to other eukaryotes, and has the ability to post-
translationally modify proteins. Furthermore, its easy
bacteria-like handling makes the parasite a promising
expression system for eukaryotic proteins. All these
characteristics suggest Leishmania to be a good choice
for the expression-secretion of recombinant antibody
fragments.
A single-chain Fragment variable (scFv) is the smallest
functional entity of a monoclonal antibody consisting of
a single-polypeptide. It is composed of the variable
regions of the heavy (VH) and the light (VL) chain of
immunoglobulins, which are connected with a flexible
amino-acid (AA) linker of varying length [9].
Antibodies, like many other proteins, are naturally
secreted. For targeted protein transport, special se-
quence motifs are usually necessary [10-12]. Secretory
signal peptides (SP) function as sorting signals. In gen-
eral, they are located at the N-terminus of proteins and
their length ranges between 15–30 AAs [13]. During
translocation across the endoplasmic reticulum mem-
brane, the SP is usually cleaved off and the protein is
entering the secretory pathway [11,13,14]. Changes of 2–4
AAs of the SP-sequence can result in new cleavage sites
and in changed expression-secretion efficiency in e.g.
lactic acid bacteria [15]. Secretory leader sequence
optimization has been widely applied in other organ-
isms as well, such as E. coli [16], different yeast strains
[17,18], or in insect cells using the baculoviral expres-
sion system [19].
In this study, we explored the use of L. tarentolae as host
for protein expression-secretion of four human recombin-
ant scFv’s derived from a semi-synthetic single-framework
phage display antibody library [20,21]. To accommodate
scFv’s with efficient cleavage sites, we followed a two step
strategy. First, we set out to in-silico model SP-sequences
in combination with suitable restriction sites for cloning
using SignalP [22]. Second, we designed appropriate
vector constructs to evaluate resulting SP-sequences in-
vivo for optimized scFv expression-secretion in L. tar-
entolae. As a starting point we utilised the commercial
L. tarentolae protein expression-secretion vector
pLEXSY-sat2 (Jena Bioscience), containing the SP-
sequence of secreted acid phosphatase 1 (SAP1 [Uni-
Prot:Q25332]) of L. mexicana [23]. This SP-sequence
has been successfully applied in a similar or the same
vector for the expression-secretion of e.g human
erythropoietin [4], C-reactive protein [24] and heterotri-
meric laminins [25].Results and discussion
In-silico analysis of natural secretory signal peptides
A number of online tools are available for predicting sig-
nal peptides and corresponding cleavage sites in protein
constructs based on their AA sequence [13]. In two
comparative studies, the online program SignalP was
identified to be the method of choice [26,27]. Thus, we
applied this online tool for cleavage site prediction using
an algorithm based on Hidden Markov Models (HMM)
on the SP-sequence in vector pLEXSY-sat2 in combin-
ation with human scFv sequences.
First, we analysed the cleavage site for natural human
IgG expression-secretion with its natural IgG VH leader
peptide [UniProt:Q9Y298] [28] in plasma cells using Sig-
nalP 3.0 [29] (MDWTWRILFLVAAATGTHA_scFv),
which resulted in a 100% cleavage prediction at the first
AA of the scFv (Figure 1A). In parallel, we compared the
cleavage site of scFv constructs with the Erwinia caroto-
vora pectate lyase 2 (pelB) leader peptide [UniProt:
P0C1C1] [30] (MKYLLPTAAAGLLLLAAQPAMA_scFv;
Figure 1B). The SP of pelB is frequently used for scFv
expression-secretion in Escherichia coli and results in the
same cleavage site as during natural human IgG
expression-secretion. Next, we analysed whether a simple
transfer of a scFv into L. tarentolae expression-secretion
vector pLEXSY-sat2 would yield the same results. En-
dogenously, the SP of SAP1 (MASRLVRVLAAAML
VAAAVSVDA_SAP1) is cleaved off completely. In-silico,
SignalP 3.0 assigns a probability of ~95% for this cleavage
event (Figure 1C). If scFv’s were theoretically to be cloned
directly in fusion with the SAP1 SP-sequence neglecting
the necessity for a cloning site, the predicted cleavage
probability is reduced to ~83% (Figure 1D). In pLEXSY-
sat2, the scFv could be cloned downstream of the SP-
sequence into the multiple cloning site II (MCS II,
underlined in the following) by using the available re-
striction site XbaI. This would result in the AA-sequence
MASRLVRVLAAAMLVAAAVSVDAGASLD_scFv. The
in-silico cleavage prediction of this construct worsens.
No unique cleavage site was assigned, rather multiple
sites were predicted with similar probabilities ranging
only around 10-30% (Figure 1E). Further, none of the
cleavage sites were predicted to yield the same cleavage
product as E. coli or human cells, i.e. targeting the first
AA of the scFv (glutamic acid (E); EVQLLES. . .), which
is defined as position 1. This is attributed to the fact that
the AA composition upstream position 1 (−1 to −3) has
an influence on the cleavage site [31]. Additionally, at
least one amino-acid is not cleaved off extending the
scFv-sequence N-terminally, which could potentially in-
fluence protein functionality. For all these reasons we
conclude that the use of the pLEXSY-sat2 vector in its
current state is not sensible for expression-secretion of





Figure 1 SignalP 3.0 analysis of different SP-sequences. Graphical output of SignalP-HMM, showing the posterior probabilities for n-, h- and
c-region and cleavage sites. (A) human IgG VH leader peptide with scFv for expression in human cells (B) Erwinia carotovora pelB SP with human
scFv for E. coli expression; (C) Leishmania mexicana secreted acid phosphatase 1 (SAP1); (D) the SAP1 SP-sequence with human scFv neglecting
any cloning strategy; (E). the SAP1 SP-sequence in pLEXSY-sat2 with scFv cloned via available XbaI RE-site.
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probability.
In-silico modification of secretory signal peptide SAP1 for
scFv expression
Modification of the SP-sequence to enhance cleavage site
probability at the first AA of scFv’s was carried out in-
silico following two rationales: First, to optimize AA
composition defined by the multi cloning site (MCS II)
accommodating unique restriction enzyme (RE) sites for
scFv cloning. Second, to find a site with the highest pos-
sible cleavage probability and lowest number of alterna-
tives at the first AA residue of the scFv. Ideally, fewer
cleavage sites predicted from SignalP and a higher prob-
ability of only one successful cleavage should lead to bet-
ter expression-secretion results of the protein.The scFv’s in our experiments were derived from the
phage display vector pIT2, which contains a unique
NcoI RE-site upstream of position 1. To enable simple
cloning, the MCS II should contain a NcoI RE-site or, al-
ternatively, a RE-site with compatible overhang, such as
PciI. Hence, in an iterative process we first set out to
modify only the MCSII by introducing changes in the
vector pLEXSY-sat2 on the nucleic acid level to accom-
modate compatible RE-sites for cloning and analysed the
results in-silico applying SignalP. This approach resulted
in the design of pLTEX-2, described in detail below. In a
second step, we included the modification of the last AA
positions of the SAP1 SP-sequence and conducted the
same analyses to obtain the desired characteristics of SP-
sequence cleavage at position 1. This approach led to
the design of vectors pLTEX-3 to pLTEX-5 (Figure 2).
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detail below.
pLTEX-2 was designed on the merit to maintain the
original SP-sequence of SAP1, only exchanging the AA
encoded by MCS II to accommodate a PciI restriction
site. The SP-sequence will be cleaved at the identical
position as in SAP1 and, hence, the scFv is extended
N-terminally by four AAs. pLTEX-2 has a predicted
major cleavage site with a probability of ~81% at the
glycine (G) residue in position −4 relative to the scFv’s
start and two minor cleavage sites at positions −7 and
−3 with probabilities of ~10% or below (Figure 2A).
The constructs pLTEX-3 to pLTEX-5 were designed to
contain a SP-sequence with a high cleavage probability
directly at position 1. To achieve this, the natural SAP1
SP-sequence was shortened by the two AA residues
aspartic acid (D) and alanine (A), corresponding to posi-
tions −6 and −5 in pLTEX-2. At the same time we intro-
duced variations in the AA residue at position −3 by










Figure 2 SignalP 3.0 analysis of novel pLTEX vectors with a scFv. Grap
n-, h- and c-region and cleavage sites of pLTEX vectors with scFv for (A) pL
sites and respective probabilities are displayed.pLTEX-3 contains an asparagine residue at position -3,
a predicted major cleavage site with a probability of
~61% at position 1 as well as two additional cleavage
sites upstream with lower probabilities (~21% and ~10%;
Figure 2B).
pLTEX-4 and pLTEX-5 contain a threonine or alanine
residue at position -3 and their predicted major cleavage
sites with a probability of close to 95% is at position 1
directly. Both constructs have additional predicted
minor cleavage sites with probabilities of below ~5%
(Figure 2C,D). The additional modification in pLTEX-4
and pLTEX-5 at the second N-terminal position of the
SP-sequence (A to T) was introduced to abolish a NcoI RE-
site in the vector and is not considered essential for the
functionality of the SP [32].
Generation of expression-secretion vectors pLTEX-1
to pLTEX-5
Novel vectors were designed based on the above consid-
erations for AA composition of SP-sequences. First, the









hical output of SignalP-HMM, showing the posterior probabilities for
TEX-2 (B) pLTEX-3, (C) pLTEX-4 and (D) pLTEX-5. Alternative cleavage
Klatt and Konthur Microbial Cell Factories 2012, 11:97 Page 5 of 10
http://www.microbialcellfactories.com/content/11/1/97To obtain stable expression of recombinant protein a line-
arised construct needs to be transfected to allow chromo-
somal integration into a predefined locus by homologous
recombination [4]. The original pLEXSY-sat2 vector (Jena
Bioscience) is linearised by RE SwaI (Figure 3A). However,
all scFv’s used in this study contain a conserved SwaI RE-
site. Therefore we replaced SwaI with EcoRV. At the same
time we reduced the pBluescript II KS (−) backbone of the
vector by 1.1 kb to enhance transformation efficiency in E.
coli generating vector pLTEX-1 (Figure 3A). Note, that
pLTEX-1 in its current state is not suitable for scFv ex-
pression according to our in-silico analysis alike pLEXSY-
sat2, since multiple cleavage sites with poor cleavage
probabilities are anticipated. Next, the cloning strategy
for scFv was determined. MCS I and MCS II were ana-
lysed for the availability of compatible restriction sites andpLEXSY-sat2
8645 bp
stuffer





























Figure 3 Description of vectors pLEXSY-sat2 and pLTEX-1 to pLTEX-5
Bioscience) was used to generate pLTEX-1 with a reduced pBluescript II KS
(B) Differences in the SP-sequences and MCS II of vectors pLEXSY-sat2 andmodified to allow cloning of scFv’s via NcoI and NotI.
During the same process, modified SP-sequences were
introduced using specific primer-sets creating expression-
secretion vectors pLTEX-2 to pLTEX-5 (Figure 3B).
In pLTEX-2 and pLTEX-3, a PciI RE-site was intro-
duced into MCS II, since PciI produces a compatible
overhang to NcoI. In vectors pLTEX-4 and pLTEX-5, a
NcoI RE-site was introduced in MCS II and at the same
time another abolished in MCS I.
Analysis of vector-dependent scFv expression rates
in vivo
To test the expression-secretion efficiency of the new
vectors pLTEX-2 to pLTEX-5, four independent scFv’s
were cloned into each vector and transfected into L. tar-
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. (A) Full vector maps of pLEXSY-sat2 and pLTEX-1. pLEXSY-sat2 (Jena
(−) backbone and different RE-sites for linearization (SwaI to EcoRV).
pLTEX-1 to pLTEX-5. Protein sequence of SP’s are underlined with red.
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and could be verified for all 16 constructs (data not
shown).
In all pLTEX vectors, protein expression occurs consti-
tutively and was tested for up to four clones per con-
struct. For each construct, the clones showed similar
expression levels according to SDS-PAGE analysis and
no difference in expression-secretion between single-
clones and multi-clones (collection of unknown number
of single-clones) from the same vector was observed
(data not shown).
First, we analysed the culture supernatant of all 16
different scFv constructs by Western blot for the pres-
ence of scFv and observed concentration differences
(Figure 4A). Independent of which scFv was cloned,
most protein could be detected in supernatants of
clones expressed in pLTEX-5 followed by pLTEX-4,
pLTEX-2 and pLTEX-3. The nature of SP-sequence
and its corresponding cleavage site can influence the
expression-secretion efficiency [15] and has a direct in-
fluence on the expression level of scFv’s.
Next, we purified scFv from the culture supernatant
of all 16 clones by immobilised metal-ion chromatog-
raphy (IMAC) and analysed the data by Coomassie-
dyed SDS-PAGE (Figure 4B). As expected, the same
order of expression efficiency was observed and the
intensity of the protein band corresponding to the
scFv (~27 kDa) was quantified densitometrically
(Figure 4C). The highest expression rate for scFv’s was
recorded from clones in vector pLTEX-5, with a me-
dian expression of 3.83 mg/L. Clones from vectors
pLTEX-4 and pLTEX-2 had a median expression rate
of 1.05 mg/L and 0.53 mg/L, respectively. The lowest
median expression rate was observed in clones from























Figure 4 Expression-secretion analysis of 16 scFv’s in vectors pLTEX-2
Detection of scFv’s with Protein L-HRP (1:5000). (B) SDS-PAGE analysis of N
4-12% Bis-Tris gels (Invitrogen). (C) Protein yield from 100 ml culture volum
densitometrical analysis on SDS-PAGE. Black circles, squares, triangles and sThe observed expression-secretion efficiencies are in
good agreement with our knowledge on SP-sequences,
formulated as the signal peptidase recognition site or
(−3, –1) rule [33] based on the analysis of 78 different
natural eukaryotic signal sequences [31]. The preference
of a small neutral AA in position −1 and exclusion of a
certain large polar, aromatic and charged AA in position
−3 can be explained by the nature of the signal peptidase
I, which is mainly responsible for SP cleavage. The fol-
lowing ranking was deduced according a ‘best fit’ ana-
lysis for AA and signal peptidase I combination for
position −1: A>G,S>C,T>Q; for position −3: A>V>
C,S,T>L,I>G [33].
In concordance with this, all our vectors follow this gen-
eral rule. In detail, our choice for alanine in position −1 re-
spectively to the cleavage site in all pLTEX vectors is
optimal. However, the AAs in position −3 are different.
Here, pLTEX-5 and pLTEX-4 have the preferred small neu-
tral AA (A, T) whereas pLTEX-2 has a hydrophobic AA
(V). The SP-sequence of pLTEX-3 has a large polar AA (N)
in position −3 resulting in poor expression, possibly due to
steric hindrance within the active site of signal peptidase I
resulting in low cleavage efficiency. The expression level is
in good agreement with the order of the AA observed
in position −3 with alanine giving the best expression-
secretion rate.
Finally, we analysed the AA-composition of the N-
terminus of all 16 obtained scFv’s by Edman degradation
[34]. In pLTEX-2 the SP is cleaved off at the predicted
glycine residue four AA downstream of the first AA
(E) of the scFv. For vectors pLTEX-4 and pLTEX-5 the
N-terminus also follows the prediction. The SP is
cleaved off at the predicted site, which is glutamic acid (E).
Additionally, a second cleavage site could be detected at






























to pLTEX-5. (A) Western blot analysis of scFv’s in culture supernatant.
i-NTA purified scFv’s from 100 ml cultures. Proteins are separated on
es grown for 72 h of IMAC-purified scFv’s determined in duplicate by
tars represent scFv-1 to −4, respectively.
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ition −5 and position −3 also fulfils the signal peptidase
recognition site rule, but with low efficiency. The observed
frequency of this cleavage isotype has become visible after
digesting large quantities of the protein (data not shown).
Surprisingly, the expected in-silico cleavage site at the
first AA of the scFv could not be confirmed in the sam-
ples derived from vector pLTEX-3. The SP was cleaved
one AA downstream at an alanine residue extending the
scFv’s. We propose that the offset of signal peptidase I
occurs as a consequence of the unfavourable AA com-
position downstream of position 1, resulting in ineffi-
cient cleavage explaining the low expression-secretion
yield.Conclusions
To our knowledge, this study represents the first in de-
tail analysis of a signal peptidase recognition site in L.
tarentolae. We could successfully demonstrate that
minor modifications in the AA-sequence of the natural
SP from SAP1 based on in-silico predictions, following
the (-3, -1) rule resulted in different expression-secretion
rates of the protein of interest. Using these generalTable 1 Vectors and constructs used in this study
Name Characteristics
pLEXSY-sat2 Expression vector pLEXSY-sat2 with sat gen
allowing selection of recombinant LEXSY st
and Amp for DH10B
pLTEX-1 Based on pLEXSY-sat2; with reduced pBlue
for vector linearization prior transfection (Sw
pLTEX-2 based on pLTEX-1; changed SP sequence
pLTEX-3 based on pLTEX-1; changed SP sequence
pLTEX-4 based on pLTEX-1; changed SP sequence
pLTEX-5 based on pLTEX-1; changed SP sequence
pLTEX-2_scFv-1 Vector for expression-secretion of scFv-1
pLTEX-3_scFv-1 Vector for expression-secretion of scFv-1
pLTEX-4_scFv-1 Vector for expression-secretion of scFv-1
pLTEX-5_scFv-1 Vector for expression-secretion of scFv-1
pLTEX-2_scFv-2 Vector for expression-secretion of scFv-2
pLTEX-3_scFv-2 Vector for expression-secretion of scFv-2
pLTEX-4_scFv-2 Vector for expression-secretion of scFv-2
pLTEX-5_scFv-2 Vector for expression-secretion of scFv-2
pLTEX-2_scFv-3 Vector for expression-secretion of scFv-3
pLTEX-3_scFv-3 Vector for expression-secretion of scFv-3
pLTEX-4_scFv-3 Vector for expression-secretion of scFv-3
pLTEX-5_scFv-3 Vector for expression-secretion of scFv-3
pLTEX-2_scFv-4 Vector for expression-secretion of scFv-4
pLTEX-3_scFv-4 Vector for expression-secretion of scFv-4
pLTEX-4_scFv-4 Vector for expression-secretion of scFv-4
pLTEX-5_scFv-4 Vector for expression-secretion of scFv-4principals the yield of scFv production could be
improved close to one order of magnitude.Methods
Generation of expression vectors pLTEX-1 to pLTEX-5
All plasmids and primers used in this study are listed in
Tables 1 and 2, respectively. Vector pLTEX-1 (Figure 3A)
was generated in three steps: First, the pBluescript II KS
(−) backbone (ori for E. coli) from pLEXSY-sat2
(Jena Bioscience) was reduced from 2.86 kb to 1.82 kb by
PCR amplification using primer 1 and 2. The primers
added EcoRV restriction sites to both ends of amplicon 1.
Secondly, the chromosomal integration cassette was PCR
amplified using primers 3 and 4 (5783 bp) from pLEXSY-
sat2. Again, the primers added EcoRV restriction site to
both ends creating amplicon 2. Next, amplicon 1 and 2
were digested with EcoRV, ligated, transformed into elec-
trocompetent DH10B cells (Invitrogen) and plated on
Ampicillin-containing agar-plates for clonal selection. The
obtained vector was named pLTEX-1P (P for precursor). In
a final step, the expression cassette was exchanged in
pLTEX-1P with a parental fragment from vector
pLEXSY-sat2. For this, both vectors were digested withReference
e (streptothricine acetyltransferase)
rains with antibiotic NTC;
Jena Bioscience
(Cat.-No. EGE-234)























Table 2 Oligonucleotides used in this study











(11) LMB3 CAG GAA ACA GCT ATG AC
(12) LEXSY_scFv_KpnI GGTGGGTACCCCGTTTGATTTCCACCTTGGTC
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purified, ligated and transformed into DH10B cells to
generate the expression vector pLTEX-1. Vectors
pLTEX-2 to −5 are based on pLTEX-1 and only differ
in the SP-sequence. Vector pLTEX-2 was generated
from pLTEX-1 and amplicon 3, which was a PCR frag-
ment from pLEXSY-sat2 using primers 3 and 5. Both,
PCR fragment and pLTEX-1 were digested with
BamHI and XbaI, ligated together and transformed
into DH10B cells to generate pLTEX-2. Vectors
pLTEX-1 and pLTEX-2 only differ in MCS II that now
contains a RE-site for PciI. Vector pLTEX-3 was gener-
ated as described for pLTEX-2, except using primer 6
instead of 5. For the generation of pLTEX-4, another
precursor (pLTEX-4P) was necessary. First, a PCR amplicon
using primers 7 (adding cutting site BglII) and 8 was gener-
ated on pLEXSY-sat2 as template. The PCR-fragment and
pLTEX-1 were then digested with BglII and KpnI, ligated
together and transformed into DH10B to generate pLTEX-
4P. In a second step, a PCR amplicon using primers 3 and
9 (adding cutting site NcoI) was generated on pLTEX-4P.
This PCR-fragment and pLTEX-1 were digested with
BamHI and XbaI, ligated and transformed into DH10B cells
to generate pLTEX-4. Vector pLTEX-5 was constructed
starting from pLTEX-4P by generating a PCR amplicon
using primers 3 and 10 (adding cutting site NcoI). Both,
PCR-fragment and pLTEX-1 were digested with BamHI
and XbaI, ligated and transformed into DH10B cells to gen-
erate pLTEX-5. All new vectors were sequence-verified by
DNA sequencing applying the Sanger method.
Cloning of antibody fragments
Individual scFv’s were PCR-amplified from the original
clones in vector pIT2 using primer 11 and 12 (adding
cutting site KpnI). The PCR-fragments (729 bp) were
digested with NcoI and KpnI for cloning, ligated into cut
vector backbones and transformed into DH10B. VectorspLTEX-2 and pLTEX-3 were digested with PciI and
KpnI, while vectors pLTEX-4 and pLTEX-5 were
digested with NcoI +KpnI. Transformants were picked
from AmpR agar-plates and sequence verified. Altogether,
16 different scFv-containing vector constructs were
designed (Table 1).
E. coli growth conditions and cell transformation
E. coli strain ‘ElectroMAXTm DH10BTm (Invitrogen;
Cat.-No. 18290–015) was grown at 37°C with 160-180 rpm
in liquid 2YT growth medium [16 g/l bacto-tryptone
(Becton, Dickinson and Company), 10 g/l bacto-yeast
extract (Becton, Dickinson and Company), 5 g/l NaCl
(Calbiochem); resuspended in Millipore water] supple-
mented with ampicillin (100 μg/ml; Roth), if necessary.
Electro-competent cells were transformed with 1 μl
(50-200 ng/μl) purified plasmid-DNA (QIAprep Spin
Miniprep Kit; Qiagen) using the ‘Micropulser Electro-
porator’ (BioRad) at 1.8 kV, 5 msec. For clonal selec-
tion, agar-plates were prepared by adding 15 g/L
bacto-agar-agar (Becton, Dickinson and Company) to
2YT growth medium, plating cells and incubating
them over night at 37°C.
L. tarentolae growth conditions and stable transfection
L. tarentolae strain P10 (Jena Bioscience) was grown at
26°C under standard air-supply in the dark in LEXSY
BHI liquid medium (Jena Bioscience) with porcine
Hemin, penicillin/streptomycin (Pen/Strep) and Nour-
seothricin (NTC; 100 μg/ml), if necessary (all additives:
Jena Bioscience). Strain P10 was passaged twice a week
by inoculation of new growth medium in flat flaks
(static) with a dilution of 1:30. Electroporation of cells
was carried out in a prechilled 2 mm electroporation cu-
vette using a Gene Pulser II with pulse controller and
capacitance extender plus (Biorad). For transfection, 5-
10 μl purified and linearized plasmid-DNA (50-
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(over night as agitated suspension culture (125 rpm);
OD600 >1.5). Cells were pulsed once at 0.45 kV and
450 μF to get 5-6 msec pulsing time with ~0.45 kV and
~20Ω, chilled shortly and cultured stationary over night at
26°C. On the next day, the majority of the culture was
dispensed onto LEXSY BHI agar plates, while the rest
was cultivated in flat flaks with new selection pressure
(NTC) to get multi-clone cultures. After 6–10 days, sin-
gle clones were picked and grown in liquid culture by
continuously increasing the volume from 0.1 ml to
10 ml in LEXSY BHI growth medium. Finally, transfec-
tion success was verified for integration of the expres-
sion cassette into the host chromosome by analytical
PCR as described [4].
Production of scFv’s expressed in Leishmania tarentolae
Positive transfectants were used for scFv-production in
100 ml of LEXSY BHI medium containing Hemin, Pen/
Strep and NTC. For this, medium was inoculated 1:30
with densely grown cultures and cultivated in agitated
suspension culture (125 rpm) for 2–3 days at 26°C until
OD600 2.5-4.5 was reached. Cells were harvested by cen-
trifugation for 18 min, at 1811 g and 4°C. Pellet and
supernatant were separated. 10 ml/l PMSF (0.1molar;
Phenylmethanesulfonyl fluoride, Sigma-Aldrich; inhibits
proteases) and 1 ml Ni-NTA agarose (Invitrogen) were
added to 100 ml supernatant and rotated for 2.5-3 h at
4°C. Ni-NTA was washed 2x with 5 ml washing buffer
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole)
and elution was carried out 4x with 1 ml elution buffer
(50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole).
All centrifugation steps were performed for 5 min, at
652 g and 4°C. Elution fractions were pooled and ana-
lysed on 4-12% Bis-Tris SDS-PAGE (Invitrogen) and
western blot after electrophoretical transfer to nitrocel-
lulose membrane. Detection of scFv’s was carried out
using Protein L-HRP (Pierce) diluted 1:5000 in 2% milk
powder in PBS with 0.1% Tween 20 and subsequent in-
cubation with CN/DAB substrate (Pierce). The protein
concentration was determined by gel densitometric ana-
lysis of the scFv bands in Coomassie-dyed SDS-PAGE
using ImageJ (Version 1.45 s). As reference, a calibration
curve on the basis of a quantifiable protein in a marker
(Precision Plus Unstained Ladder, 25 kDa band, 0.12 –
1.2 μg protein) or a scFv expressed in E. coli was estab-
lished and used for calculating the protein concentration
applying linear regression equation. N-terminal scFv’s
analysis by Edman degradation was undertaken by
Proteome Factory (Berlin, Germany).
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